Dr. Jennifer Bath, CEO & President of ImmunoPrecise Antibodies Ltd. IPA was recently interviewed by Benzinga. ImmunoPrecise is a biotherapeutic research…
IPA , an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its second quarter of the 2024 fiscal year , which ended October 31,.
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
ImmunoPrecise Antibodies (NASDAQ: IPA) (“IPA”), a leading company in AI-driven biotherapeutic research and technology, has recently announced important changes to its Board of Directors and upcoming financial reporting activities.